Fate Therapeutics (FATE) Reports In-Line Q4 EPS

Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.44), in-line with the analyst estimate of ($0.44). Revenue for the quarter came in at $1.86 million versus the consensus estimate of $1.58 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Allison Transmission to Join S&P MidCap 400; Goodyear Tire & Rubber to Join S&P SmallCap 600
• Constellation Brands (STZ) Tops Q1 EPS by 18c
• Invitation Homes prices $500 million senior notes offering at 4.950%